◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksJAZZ › Net Income

Jazz Pharmaceuticals PLC (JAZZ) Net Income 2006–TTM

DATA UPDATED 2026-09-19

Jazz Pharmaceuticals PLC annual net income for fiscal TTM was $940 million, compared with -$356 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

JAZZ Annual Net Income

Net Income (annual)TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Net Income$940M($356M)$560M$415M($224M)($329M)$239M$523M$447M$488M$397M$330M$58M$216M$289M$125M$33M($7M)($184M)($139M)($59M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JAZZ Quarterly Net Income

Net Income (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Net Income$193M$293M$203M$251M($718M)($93M)$191M$215M$169M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

More JAZZ metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All JAZZ financial statements → Interactive JAZZ charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.